INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

CANCER RESEARCH

AMER ASSOC CANCER RESEARCH

1. GlaxoSmithKline
2. Merck Co, Inc